Influenza Vaccination Reduces Major Adverse Cardiovascular Events

Written by The Life Science Feed Editorial Team · Published 30 August 2026 · Edited by Mara Voss

> Patients with established cardiovascular disease face increased morbidity and mortality following influenza infection. The question of whether influenza vaccination confers direct cardioprotection, beyond preventing respiratory illness, has been a subject of ongoing clinical interest. Evidence indicates that influenza vaccination significantly reduces the incidence of major adverse cardiovascular events (MACE) in susceptible populations.

KEY TAKEAWAYS

- The Pivot: Influenza vaccination is increasingly recognized for its direct cardioprotective effects, not solely for respiratory disease prevention.
- The Data: Meta-analyses and large observational studies consistently show a reduction in MACE, including myocardial infarction and stroke, following influenza vaccination.
- The Action: Clinicians should emphasize influenza vaccination as a critical component of secondary prevention strategies for patients with cardiovascular disease.

Influenza infection is associated with an elevated risk of acute myocardial infarction, stroke, and other major adverse cardiovascular events (MACE). This risk is particularly pronounced in individuals with pre-existing cardiovascular conditions, including coronary artery disease, heart failure, and peripheral artery disease. The mechanisms proposed for this association include systemic inflammation, endothelial dysfunction, plaque instability, and increased thrombogenicity triggered by the influenza virus. Consequently, preventing influenza infection through vaccination has been investigated for its potential to mitigate these cardiovascular risks.

Clinical Evidence for Cardioprotection

Multiple studies have examined the relationship between influenza vaccination and cardiovascular outcomes. A meta-analysis of randomised controlled trials and observational studies, for instance, demonstrated a consistent reduction in MACE among vaccinated individuals. Specifically, influenza vaccination was associated with a reduction in the risk of MACE, with hazard ratios typically ranging from 0.64 to 0.75 across various cohorts. This effect was observed in patients with stable cardiovascular disease, acute coronary syndromes, and those undergoing percutaneous coronary intervention.

One large-scale observational study involving over 100,000 patients with cardiovascular disease reported that influenza vaccination was associated with a 28% reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke over a follow-up period of one year. The absolute risk reduction was 2.1%, translating to a number needed to treat of approximately 48 to prevent one MACE. These benefits were independent of traditional

cardiovascular risk factors and other preventive therapies.
Further analysis has shown that the cardioprotective effect is more pronounced in patients with higher baseline cardiovascular risk. For example, individuals with a recent acute coronary syndrome who received influenza vaccination experienced a greater relative risk reduction in subsequent MACE compared to those with stable angina. This suggests that the anti-inflammatory and immunomodulatory effects of vaccination may be particularly beneficial during periods of heightened cardiovascular vulnerability.
The timing of vaccination also appears to be relevant. Studies indicate that vaccination administered prior to the peak influenza season confers optimal protection. The efficacy of the vaccine in preventing cardiovascular events is influenced by the match between the vaccine strain and circulating viral strains, as well as the individual's immune response. Despite these variables, the overall evidence supports a net clinical benefit.

Limitations and Future Directions

While the evidence for cardioprotection through influenza vaccination is compelling, certain limitations warrant consideration. Most data originate from observational studies, which, despite rigorous adjustment for confounders, cannot definitively exclude residual confounding. Randomised controlled trials specifically powered to assess cardiovascular endpoints are fewer but generally corroborate the findings from observational cohorts. Heterogeneity in study populations, vaccine types, and influenza seasons can also influence the generalisability of results.
Future research should focus on elucidating the precise immunological mechanisms by which influenza vaccination confers cardioprotection. Investigating the impact of different vaccine formulations (e.g., high-dose vaccines) on cardiovascular outcomes in specific high-risk subgroups could also refine current recommendations. Additionally, studies exploring the cost-effectiveness of influenza vaccination as a cardiovascular preventive strategy would provide valuable information for healthcare policy decisions.

Clinical Implications and Recommendations

Given the robust and consistent evidence, influenza vaccination should be strongly recommended for all individuals, particularly those with pre-existing cardiovascular disease. This recommendation aligns with current guidelines from major cardiology and public health organizations. Healthcare professionals should actively promote influenza vaccination as an integral component of comprehensive cardiovascular risk management, alongside traditional strategies such as lipid-lowering therapy, blood pressure control, and antiplatelet agents.

The observed number needed to treat (NNT) of approximately 48 to prevent one MACE underscores the significant public health impact of widespread vaccination. This NNT is comparable to or even more favorable than that of some commonly prescribed cardiovascular medications in certain populations. Integrating influenza vaccination into routine clinical practice for cardiovascular patients could therefore lead to substantial reductions in cardiovascular morbidity and mortality, thereby alleviating the burden on healthcare systems.

Further efforts are needed to improve vaccination rates, especially among high-risk populations. Educational initiatives targeting both healthcare providers and patients can help address misconceptions and highlight the dual benefit

of influenza vaccination in preventing respiratory illness and reducing cardiovascular events. Emphasizing the cardioprotective benefits may serve as an additional motivator for vaccine uptake.

CLINICAL IMPLICATIONS

The accumulating evidence for influenza vaccination's direct cardioprotective effects should prompt a re-evaluation of its role in cardiovascular disease management. It is no longer sufficient to view influenza vaccination solely as a respiratory health measure; it is a legitimate secondary prevention strategy. General practitioners and specialists alike must integrate this understanding into their patient counselling, moving beyond a perfunctory recommendation to an emphatic endorsement, particularly for those with established cardiovascular disease.

For clinicians, this means actively identifying and vaccinating all eligible cardiovascular patients. The data supports a clear benefit, and the absence of specific guidelines from major cardiology societies explicitly endorsing influenza vaccination for MACE reduction represents a gap that needs addressing. While the European Society of Cardiology and American Heart Association acknowledge the general benefits, a stronger, more prescriptive stance on its cardioprotective role would reinforce its importance among practitioners.

The pharmaceutical industry, which often focuses on novel drug development, should also recognise the untapped potential in promoting existing, cost-effective interventions like influenza vaccination. Public health campaigns, often underfunded, could benefit from industry collaboration to highlight these broader benefits. Ultimately, ensuring high vaccination rates in at-risk populations is a low-cost, high-impact intervention that can reduce cardiovascular morbidity and mortality, a goal that aligns with both patient well-being and healthcare system efficiency.

REFERENCES

1. 1. Heidecker B, Libby P, Vassiliou VS, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. Eur Heart J. 2025;46(36):3518-3531. doi:10.1093/eurheartj/ehaf384
2. 2. Maniar YM, Al-Abdouh A, Michos ED. Influenza Vaccination for Cardiovascular Prevention: Further Insights from the IAMI Trial and an Updated Meta-analysis. Curr Cardiol Rep. 2022;24(10):1327-1335. doi:10.1007/s11886-022-01748-8
3. 3. Sedrak P, Dounaevskaia V, Mancini GBJ, et al. Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review. CJC Open. 2025;7(10):1375-1388. doi:10.1016/j.cjco.2025.09.004
4. 4. Vollaard AM, Slok ENE, van Dijkman PRM, Dekkers OM, Groeneveld GH. [Influenza vaccination as secondary prevention for cardiovascular disease]. Ned Tijdschr Geneeskd. 2023;167. PMID:37823884
5. 5. Guo J, Wang T, Liu Z, et al. Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference. EClinicalMedicine. 2025;87:103449. doi:10.1016/j.eclinm.2025.103449
6. 6. Cai M, Xie Y, Al-Aly Z. 2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans. JAMA Intern Med. 2026. doi:10.1001/jamainternmed.2026.1929

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com